Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by complement and innate immune dysfunction leading to increased susceptibility to infection and higher infection-related mortality. While hemoperfusion has been explored in inflammatory and immunocompromised states, reports of its use with broad-spectrum adsorbent cartridges such as HA 330 in SLE remain scarce.
A 54-year-old female newly diagnosed case of SLE who underwent methylprednisolone pulse therapy in March 2025 and maintained on daily Prednisone 25 mg, Hydroxychloroquine 200 mg, and Mycophenolate mofetil 500 mg was admitted for evaluation of melena.
She was hemodynamically stable but markedly pale, with laboratory findings of severe anemia (Hgb 26 g/L), leukopenia (3.87 ×10⁹/L), lymphopenia (0.23%), hypoalbuminemia (20.1 g/L), and elevated serum creatinine (1.44 mg/dL). Urinalysis showed trace albuminuria, hematuria (3 RBCs/hpf), and pyuria (49 WBCs/hpf). Physical examination was unremarkable except for grade I bipedal edema.Chest X-ray was normal.
After correction of anemia (Hgb 103 g/L), EGD revealed Forrest III duodenal ulcer, erosive gastroduodenitis, and Helicobacter pylori infection. During hospitalization, she developed hypotension (80/60 mmHg), productive cough, chills, desaturation (90–92%), and bilateral coarse crackles. Vasopressors and empiric Piperacillin-Tazobactam were started for hospital-acquired pneumonia. Inflammatory markers were markedly elevated (procalcitonin >100 ng/mL, CRP 49.6 mg/L) with leukocytosis (14.5 ×10⁹/L) and rising creatinine (1.93 mg/dL). Sputum culture grew Acinetobacter baumannii; blood cultures grew Staphylococcus aureus and S. epidermidis.
Intermittent hemodialysis with Jafron HA330 hemoperfusion was administered daily for three consecutive days. Following the initial hemoperfusion session, the patient’s blood pressure stabilized at 130/90 mmHg without need for further vasopressor support. After completion of three sessions, the patient demonstrated clinical improvement with marked decline in inflammatory markers: procalcitonin (1.29 ng/mL), C-reactive protein (4.5 mg/L), reduction in serum creatinine (1.4 mg/dL) and resolution of leukocytosis (5 × 10⁹/L) (Table 1). Follow-up chest radiograph showed significant improvement in pulmonary infiltrates and congestion (Figure 1).
Emerging evidence supports the use of hemoperfusion as an adjunctive therapy in managing severe infections owing to its ability to adsorb pro‑inflammatory cytokines and protein-bound toxins. In the case reported, the use of HA330 in hemoperfusion significantly reduced inflammatory markers in the setting of an underlying autoimmune condition (SLE) suggesting immunomodulatory benefits beyond toxin removal.
